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Abstract
Background: Malaria in pregnancy is characterised by the sequestration of Plasmodium falciparum-
infected erythrocytes in placental intervillous spaces. Placental parasites express a specific
phenotype, which allows them to cytoadhere to chondroitin sulfate A expressed by
syncytiotrophoblasts. Malaria infection during pregnancy allows the acquisition of antibodies against
placental parasites, these antibodies are thought to be involved in protection during subsequent
pregnancies.
Methods: To investigate the development of a cellular response to placental parasites during
pregnancy, peripheral blood mononuclear cells were collected from women at the time of their
confinement. The study was performed in Cameroon where malaria transmission is perennial. In
vitro cell proliferation and cytokine production were measured in response to non-malarial
activators (concanavalin A and PPD), a recombinant protein from P. falciparum MSP-1, and
erythrocytes infected by two P. falciparum lines, RP5 and W2. Like placental parasites, the RP5 line,
but not W2, adheres to chondroitin sulfate A and to syncytiotrophoblasts.
Results: The proliferative response to all antigens was lower for cells obtained at delivery than 3
months later. Most interestingly, the cellular response to the RP5 line of P. falciparum was closely
related to parity. The prevalence rate and the levels of response gradually increased with the
number of previous pregnancies. No such relationship was observed with W2 line, or MSP-1
antigen.
Conclusions: This suggests the occurrence of an immune response more specific for the RP5 line
in women having had multiple pregnancies, and who are likely to develop immunity to pregnancy-
associated parasites. Both humoral and cellular mechanisms may account for the lower
susceptibility of multigravidae to malaria.
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Background
Malaria during pregnancy is a priority area for malaria re-
search and control. Placental malaria is a common com-
plication of pregnancy-associated malaria associated with
foetal abortion and stillbirth, and is responsible for low
birth weight of the offspring. Several epidemiological
studies demonstrated these effects are most frequent and
marked in primigravidae [1,2]. The factors responsible for
the increase in malaria susceptibility during pregnancy,
particularly during the first pregnancy, have not been fully
elucidated.
Pregnancy-associated malaria is characterized by the se-
questration of Plasmodium falciparum-infected erythro-
cytes in placental intervillous spaces. Placental parasites
appear to express a specific phenotype defined by the ad-
herence of P. falciparum-infected erythrocytes to the gly-
cosaminoglycans chondroitin sulfate A (CSA) and
hyaluronic acid, expressed by the syncytiotrophoblast
[3,4]. Parasite adhesion to CSA is mediated by P. falci-
parum-variant surface antigens (VSAs) expressed on the
surface of infected erythrocytes [5,6]. Placental parasites
bind to CSA and not to other VSAs ligands, such as CD36
and ICAM-1, whereas the opposite is true for most para-
site isolates from non-pregnant individuals [3,4,7]. The
expression of this particular VSA by parasites binding to
CSA in the placenta is thought to be the basis for the high-
er susceptibility of primigravidae. These women have not
been exposed to and have no immunity to such parasites
before becoming pregnant. The first pregnancy enables
them to develop specific immunity, which protects them
during subsequent pregnancies. This hypothesis is sup-
ported by the fact that multigravid pregnant women in en-
demic areas have antibodies to placental parasites
acquired during previous malaria-infected pregnancies
[8], and that these antibodies inhibit the cytoadherence of
placental parasites to human syncytiotrophoblasts [9].
Pregnancy is characterised by a transient depression of
cell-mediated immunity of the woman that allows foetal
allograft retention, but also interferes with resistance of
the mother to various infectious diseases [10]. Cellular
immune responses to P. falciparum antigens are depressed
in pregnant women in comparison with non-pregnant
controls [11,12]. This pregnancy-induced immunosup-
pression may persist several months after delivery restora-
tion of immune responses to P. falciparum antigens being
observed within six months after delivery [13,14].
In this study, the cellular responses in women at the time
of delivery as well as in women 3 months after delivery
were assessed. In vitro lymphocyte proliferation and cy-
tokine production were measured for cells obtained from
women living in Yaounde, Cameroon, where malaria
transmission is perennial. The results were analysed ac-
cording to parasite infection of the placenta and gravidity
status.
Materials and Methods
Study site, donors and blood sample collection
The study took place in Yaounde, Cameroon, a rainforest
area with hyperendemic P. falciparum malaria and peren-
nial transmission. Women delivering at the maternity
wards of Nkoldongo and Djoungolo between June 1998
and January 1999 were enrolled after informed consent
was obtained. To aid the identification of women with a
placental malaria infection, a thick peripheral blood
smear was obtained before delivery and examined for par-
asites. Following identification of an infected individual,
the next uninfected woman of same parity presenting to
the maternity wards was also enrolled. Term placentas
and 10 ml heparinized venous blood samples were col-
lected immediately after delivery. Thick smears of blood
from the maternal side of the placenta were examined for
the presence of pigment, parasites, or both. Another group
of women were studied three (± 1) months after delivery,
and 10 ml heparinized venous blood sample was drawn.
Antigens
Concanavalin A (CA; Sigma, St Louis, Mo) was used at a
final concentration of 10 µg/ml. The recall antigen tuber-
culin purified protein derivative (PPD; Statens Serum In-
stitut, Copenhagen, Denmark) was used at a final
concentration of 12.5 µg/ml. The Escherichia coli-ex-
pressed rMSP119 protein based on P. falciparum Merozoite
Surface Protein 1 (MSP-1), was cleaved from a GST-fusion
protein and used at a final concentration of 5 µg/ml [15].
Two P. falciparum lines were used as antigens following in
vitro culture. Erythrocytes infected with the RP5 P. falci-
parum line (a gift from Dr. J. Gysin, Laboratoire de Géné-
tique et d'Immunologie, Marseille, France) bind to CSA
and not to other known receptors of P. falciparum [16]
and, consequently, bind to human syncytiotrophoblasts
[17], as do pregnancy-associated parasites [8]. Fortnightly,
the binding phenotype was selected and checked using
CSA-coated Petri dishes [9]. The unselected W2 P. falci-
parum line does not bind to CSA, nor to human syncytio-
trophoblasts (data not shown). Infected erythrocytes were
obtained from unsynchronised in vitro cultures at a 5 %
haematocrit in RPMI 1640 Hepes and 10 % heat-inacti-
vated human AB serum. Cells were harvested at 5 % para-
site density by centrifugation and used to stimulate
cultures at 10 % haematocrit. A 100 µl aliquot, corre-
sponding to 5.106 parasitized erythrocytes, was placed in
each well.
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Isolation and culture of peripheral blood mononuclear 
cells
Peripheral blood mononuclear cells (PBMC) were isolat-
ed on Ficoll-Paque® (Pharmacia, Uppsala, Sweden), and
cell viability was confirmed by trypan-blue staining. Puri-
fied PBMC were suspended at 106 cells/ml in buffered
RPMI 1640 containing 10 % human serum, and 100 µl al-
iquots were placed in triplicate in round bottom 96-well
plates. Antigens, infected erythrocytes, non-infected eryth-
rocytes (NIE), or medium alone were added in 100 µl
amounts at the indicated concentrations. Plates were incu-
bated at 37°C in a humidified chamber with 5% CO2 for
3 or 6 days. The 3- and 6-day culture supernatants from
each triplicate were pooled and stored at -80°C.
After 6 days, 110 µl were removed from culture superna-
tants and 50 µl fresh medium containing 0.5 µCi methyl-
[3H]-thymidine (specific activity 2 Ci/mmole, Amersham,
Les Ulis, France) were added to each well. After a further
16 hr, cells were collected on glass-fiber filters and incor-
porated radioactivity was measured. Stimulation indices
(SI) were calculated by dividing the geometric mean cpm
of antigen-stimulated cultures by the geometric mean
cpm of unstimulated cultures. A positive response for all
antigens was defined as a SI = 2.5 [12].
Measurement of cytokine levels in supernatants
IL-2, IL-4, IL-10, and IFN-γ concentrations were measured
in culture supernatants by a sandwich ELISA method, us-
ing manufacturer's instructions (CLB Amsterdam, The
Netherlands). The detection limit was 5 pg/mL for IL-2,
0.4 pg/mL for IL-4, 3 pg/mL for IL-10, and 2 pg/mL for
IFN-γ. Values below this threshold were assigned a value
of half the detection limit. For statistical analysis, cytokine
concentrations in supernatants of unstimulated cultures
or in the presence of NIE were subtracted from the values
obtained for supernatants of antigen-stimulated cultures,
and resulting values were used to define responders and
non-responders.
Statistical analyses
Differences in prevalence rates between groups were test-
ed by the Chi-square test or the Chi-square test for trend.
Differences between groups were analysed by non-para-
metric methods (Mann-Whitney U-test). A logistic regres-
sion using the maximum likelihood ratio method (LR
procedure of BMDP) was used to adjust immune respons-
es simultaneously on parity status and infection or age.
The significance limit was p = 0.05.
Results
A total of 47 women were enrolled at delivery, and 41 (in-
cluding 15 of these) were investigated 3 months after de-
livery. Among the former, 17 were primigravidae (mean
age: 18.8 ± 1.7 years; 7 having presented with a placental
infection) and 30 multigravidae (mean age: 26.1 ± 4.2
years; 15 having presented with a placental infection).
Among the latter, 17 were primigravidae (mean age: 20.8
± 3.6 years; 9 having presented with a placental infection)
and 24 multigravidae (mean age: 26.1 ± 5.0 years; 12 hav-
ing presented with a placental infection). The two groups
of women investigated at delivery and 3 months after de-
livery were similar, as regards to age, parity, area of resi-
dence, and season of bleeding (all p > 0.2).
In the presence of concanavalin A and PPD, lymphocytes
from most women proliferated whether these cells were
collected at delivery or 3 months later. Both the preva-
lence rates and the mean levels in the proliferation assay
were higher 3 months after delivery than at delivery (Table
1). The prevalence rate of women whose cells proliferated
in response to MSP-1 or RP5, but not to W2, was also sig-
nificantly higher 3 months after delivery than at delivery.
Similarly, the mean level of responses was higher. No dif-
ferences were found on proliferation responses at delivery
according to parity and malaria status (all p > 0.1), where-
as these differences in response to RP5 after delivery ap-
peared to be related to both the occurrence of a P.
falciparum infection of the placenta, and to the parity sta-
tus of the woman. Three months after delivery, cell prolif-
eration in response to RP5 was observed in 53 % of the
mothers who had a parasite-positive placenta at delivery,
while cells from only 17 % of the other women proliferat-
ed (p = 0.02) (see Fig. 1A). The mean levels of responses
to RP5 were also increased in women who had presented
with a malarial infection of the placenta three months ear-
lier (2.4 (1.4 – 4.0) vs. 1.4 (1.0 – 1.9), Mann-Whitney U-
test, p = 0.07). Likewise, cells from 50 % of multiparous
women proliferated in response to RP5, while those of
only 18 % of primiparous proliferated (p = 0.04) (Fig.
1B). This difference was also observed for the mean level
of response, which was higher in multiparous women
(2.3 (1.4 – 3.7) vs. 1.4 (1.0 – 2.0), Mann-Whitney U-test,
p = 0.08). Logistic regression demonstrated that both pla-
cental infection (p = 0.03) and parity (p = 0.05) were in-
dependent predictors of the proliferative response to RP5.
No such difference was observed with either the MSP-1
antigen or the W2 P. falciparum strain.
The in vitro production of IFN-γ, IL-2, IL-10, and IL-4 was
investigated three months after delivery and compared ac-
cording to parity and to placenta malaria status at deliv-
ery. No difference in cytokine response was observed with
respect to placenta malarial status at delivery (i. e. with or
without placental infection) (Fig. 1A). However, consider-
ing the parity status (primiparous versus multiparous) dif-
ferences were observed in cytokine production, especially
in response to RP5 (Fig. 1B). The prevalence rates of IL-2
production were increased in multiparous women (all p =
0.05) (Fig. 1B) in response to the three malaria antigens,
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while no differences were observed with concanavalin A
or PPD. The prevalence of production of IL-2 and IL-4 by
cells from multiparous women was twice as high (both p
< 0.02), and a similar trend was observed for IFN-γ and IL-
10, although the differences did not reach significance (p
= 0.16 and 0.08 respectively). Moreover, the prevalence
rate of responses to RP5 gradually increased with parity
(Fig. 2), this increase being significant for lymphocyte
proliferation and IL2 and IL4 production (Chi2 test for
trend, p = 0.01, 0.002 and 0.05, respectively). Such parity-
related changes were not observed with the other malarial
antigens. Among multiparous women, except in the case
of IL2 production in presence of W2, these responses did
Figure 1
In vitro proliferative (LPA) and cytokine prevalence rates of response of peripheral blood mononuclear cells from Cameroonian
women 3 months after delivery. Panel A, women having presented (n = 20, white) or not (n = 21, black) with a P. falciparum
infection of the placenta; panel B, primiparae (n = 17, black) and multiparae (n = 24, white). Stars indicate significant differences
(Chi2 test). ConA: concanavalin A; PPD: tuberculin purified protein derivative; MSP1: recombinant protein from P. falciparum
merozoite surface protein-1; RP5 and W2: erythrocytes infected with the RP5 and W2 P. falciparum lines, respectively.
Table 1: In vitro proliferative responses of peripheral blood mononuclear cells collected at delivery and 3 months later from Cameroo-
nian womena.
Delivery (n = 47) 3 months after (n = 41) Pb Pc
%+ Mean %+ Mean %+ Mean
ConA 76.6 7.0 (5.1–9.7) 88.9 9.3 (6.5–13.4) 0.13 0.25
PPD 85.1 10.4 (7.5–14.6) 100.0 24.4 (18.6–32.0) 0.016 0.0005
MSP1 8.1 0.9 (0.7–1.1) 32.4 1.6 (1.1–2.3) 0.002 0.05
RP5 17.9 1.2 (0.9–1.7) 35.1 1.9 (1.4–2.5) 0.05 0.09
W2 10.9 1.1 (0.9–1.4) 16.2 0.9 (0.6–1.3) 0.47 0.44
a Data are expressed as prevalence rates and geometric means (95 % confidence interval) of stimulation indices. >b P value of the difference in prev-
alence rates, Chi2 test c P value of the difference in mean levels, Mann-Whitney U-test
Malaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/16
Page 5 of 8
(page number not for citation purposes)
not increase with parity (Fig. 2). The prevalence rates of IL-
10 response to MSP-1 decreased with parity (p = 0.04).
The geometric mean levels of production of all cytokines
in response to concanavalin A, as well as those of IFN-γ
and IL-2 in response to PPD were 10 times higher than re-
sponses to the three malaria antigens (Fig. 3). The level of
production of these cytokines in response to RP5 was also
increased also two to six times higher in cells from mul-
tiparous women, and the difference was significant for IL-
2 and IL-4 (5.1 vs 1.5 pg/ml, 5.3 vs 0.5 pg/ml respectively;
all p < 0.04). In contrast, the responses to the other anti-
gens were only moderately affected by the parity status.
IL2 production in the presence of RP5 or W2 also in-
creased with age in an univariate analysis, but logistic re-
gression demonstrated that parity remained the only
independent predictor of the IL2 response to RP5 (p =
0.02) and W2 (p = 0.005).
Discussion
Pregnancy is an immunological balancing act in which
the mother's immune system has to remain tolerant to the
foetus and yet maintain immune competence for defense
against microorganisms. Several studies have documented
a decrease of cell-mediated immune responses to malaria
parasite antigens during pregnancy [9,13,18] and early
post-partum [11,14] in association with increased suscep-
tibility to malaria. Consequently, the exploration of P. fal-
ciparum specific immune responses performed during this
time is unlikely to produce results that are easy to inter-
pret. Our rationale for not investigating cytokine secretion
at delivery, but for performing full analysis of the cellular
immune response three months after delivery, was that we
expected that immunosuppression would be abolished by
this time. Indeed, we confirmed an important systemic
lowering of the malaria-specific and non-specific cellular
responses, as the proliferative response of peripheral
blood mononuclear cells was highly reduced at delivery,
as compared to three months later.
Regarding the relationship between parity status and cel-
lular responses to the three P. falciparum antigens used,
different profiles were observed. IL2 prevalence rate in re-
sponse to all malaria antigens gradually increased with
the number of previous parities, independent of age, sug-
gesting the construction of T cell memory during succes-
sive pregnancies. In response to the RP5 line, the
prevalence rate and the level of response increased with
the number of previous parities in most of the assays used.
This relationship was only evident for IL2 in responses to
the other P. falciparum line or a recombinant protein
based on MSP-1, an antigen shared by all P. falciparum
lines. This demonstrates the occurrence of an immune re-
sponse that is more specific for a parasite phenotype ex-
pressed by the RP5 line in women who have had repeated
Figure 2
In vitro proliferative and cytokine prevalence rates of
response to MSP1 (recombinant protein from P. falciparum
Merozoite Surface Protein-1), or to erythrocytes infected
with the RP5 or the W2 P. falciparum strain from peripheral
blood mononuclear cells collected 3 months after first (n =
17, white), second (n = 9, grey), third (n = 7, stripped), or =
fourth (n = 8, black) delivery in Cameroonian women.
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pregnancies. The RP5 line of P. falciparum expresses the
specific cytoadherence properties of the pregnancy-associ-
ated parasites, whereas the W2 line does not cytoadhere to
syncytiotrophoblast (Maubert, unpublished data). How-
ever, P. falciparum lines might not be the most appropriate
tool to dissect the immune response, as numerous anti-
gens are implicated.
Pregnancy-associated parasites adhere to CSA expressed
on the placental endothelium, representing a phenotype
that is not shared with parasites isolated from non-preg-
nant hosts, but that is expressed by the RP5 line. Several
molecules on the surface of infected erythrocytes suggest-
ed as acting as counter-receptors for these epithelial mol-
ecules and the major adherence receptor appears to be
PfEMP-1 [6]. PfEMP-1 molecules are highly antigenic and
are encoded by a diverse multigene family, and expression
on the surface of erythrocytes can switch during the course
of a clonal infection [19]. The hypothesis [3] that the
strains of P. falciparum implicated in placental malaria are
representative of a unique sub-population, was recently
supported by the demonstration that the expressed
PfEMP-1 in infected placental parasite samples are closely
related to each other [20]
Among pregnant women, primiparous women with a
non-infected placenta have the highest likelihood of never
having been infected with pregnancy-associated parasites.
However, even in these women, an infection may have oc-
curred during early pregnancy, explaining why some of
them had raised responses to the RP5 strain after delivery.
The higher proportion of multiparous women that re-
sponded to the RP5 strain probably reflects a pregnancy-
associated parasite-specific immunization during a previ-
ous parasitized pregnancy. This likelihood of having been
infected, as well as the proportion of responders, increases
with parity. In line with our data, a previous report dem-
onstrated that the acquisition of antibodies against the
RP5 line and against CSA-adhering parasites correlated
with the number of past pregnancies [8,21]. Moreover,
antibodies directed against CSA-adhering parasites and
acquired during an infected pregnancy inhibited the cy-
toadherence of CSA-adhering parasites to human syncyti-
otrophoblasts [22]. It is likely that women having
multiple pregnancies, who develop an immune response
to RP5, are developing immunity to pregnancy-associated
parasites, thereby decreasing the risk of pregnancy-associ-
ated malaria during subsequent pregnancies. Moore et al.
[23] proposed a model in which re-circulation of memory
T lymphocytes from the intervillous blood to local lym-
Figure 3
In vitro cytokine production in response to Con A: concanavalin A; PPD: tuberculin purified protein derivative; MSP1: recom-
binant protein from P. falciparum Merozoite Surface Protein-1; RP5 and W2: erythrocytes infected with the RP5 and W2 P. fal-
ciparum strains, respectively from peripheral blood mononuclear cells collected 3 months after delivery in Cameroonian
women. Figure shows the geometric means of responders and the 95% CI.
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phoid tissue facilitates the maintenance of local immuni-
ty. Both cellular and humoral components may account
for the lower susceptibility of multigravidae to malaria.
Understanding the mechanisms involved in protection of
multigravidae to placental malaria will have consequenc-
es in public health management, both in terms of drug-
based control measures and malaria vaccines. Indeed, to
limit costs, some countries advise restricting drug prophy-
laxis against malaria during pregnancy to the primiparae,
the most sensitive group of women. As the lower suscep-
tibility of multiparae may rely on an earlier exposure and
immunization against placental parasites, a total preven-
tion of malaria during the first pregnancy may inhibit the
development of immune responses against pregnancy-as-
sociated parasites. However, no difference in susceptibili-
ty to malaria was observed during the second pregnancy
of women who had or had not received drug prophylaxis
during their first pregnancy [24]. This is probably because,
in areas in which malaria is endemic, prophylaxis is rarely
taken before the fifth or sixth month of pregnancy, and its
efficacy is frequently impaired by drug resistance. It is like-
ly that drug prophylaxis will limit placental colonization,
without inhibiting the development of specific immunity.
The consequence of our findings has implications for the
design of a malaria vaccine. Bull and colleagues reported
that protection against disease is dependent on a variant-
specific immune response directed against VSAs that
probably include members of the PfEMP-1 family [25].
This supports the idea that PfEMP-1 could be used to de-
velop an anti-disease vaccine, although the large size of
the PfEMP-1 family raises doubts about the feasibility of
this approach. In the case of pregnancy-associated malar-
ia, the number of antigenic variants may be very small,
and therefore PfEMP-1 may be a good vaccine candidate
for pregnancy-associated malaria. Further studies using
specific antigen from placental malaria parasites will pro-
vide additional information about the development of
both cellular and humoral immunity in pregnant women.
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